Login to Your Account


DUBLIN – Apeiron Biologics AG gained formal European Commission approval last week for dinutuximab beta as a treatment for pediatric neuroblastoma, a historic milestone for the Austrian biotech company and one that puts it on a firm financial footing.

LONDON – Two new reports from the European Commission (EC) and EMA show that 10 years on from the first approval biosimilars are having a major impact on price and patient access and there is no evidence of any differences in safety and efficacy compared to reference products.

LONDON – The majority of drugs paid for by a fund set up to provide access to the new wave of expensive cancer therapies failed to show any evidence of meaningful clinical benefit and may have resulted in patients suffering unnecessarily from toxic side effects.

More EUROPE Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: